Skip to main content
padlock icon - secure page this page is secure

Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E

Buy Article:

$36.50 + tax (Refund Policy)

The development of anti–immunoglobulin E (IgE) antibodies for prophylactic and therapeutic applications in allergic diseases has taken nearly 20 years. Limited usage has been approved for allergic asthma. The usage in other allergic indications is in active development and may take an additional 5–10 years. The current therapeutic anti-IgE, which includes two humanized recombinant monoclonal antibodies, is the result of rational drug design, taking into consideration the structural features of IgE and membrane-bound IgE (mIgE) and various techniques collectively referred to as antibody engineering. Unlike ordinary antibodies specific for human IgE, a therapeutic anti-IgE, although capable of binding tightly to free IgE and mIgE, does not bind to IgE bound by the high-affinity IgE.Fc receptors (Fc∈RI) on mast cells and basophils and by the low-affinity IgE.Fc receptors (Fc∈RII, or CD23) on B cells, granulocytes, and many other cell types. The therapeutic anti-IgE is efficacious in treating allergic patients in whom IgE mediates the major allergic responses. It possesses multiple potential pharmacologic effects; researchers still are uncovering its previously unknown immunoregulatory effects. The human studies of the therapeutic anti-IgE have gradually settled many controversial views relating to IgE, such as the roles of IgE in the pathogenesis of asthma, immune defense, and early and late-phase reactions of allergic responses. Studies on the unique structural mIgE C∈mX domain and on the regulatory effects of anti-C∈mX monoclonal antibodies will be an area for future investigation of the potential of long-term IgE regulation.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: March 1, 2006

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more